ÂÜÀòÂÒÂ×

Dr. Artis joined Annexon as CSO in January 2023. Dr. Artis most recently served as CSO at Octant Bio and earlier, he served as Senior Vice President, Chemistry at Annexon where he led the efforts on small molecule classical complement inhibitors that resulted in the nomination of ANX1502 as a development candidate. He previously served as Senior Vice President, Research at Elan Pharmaceuticals, Vice President, Lead Generation at Plexxikon and held positions of increasing responsibility at Genentech and Syntex. He has co-authored over 45 papers, been recognized as a co-inventor on 45 issued U.S. patents and made direct contributions to seven molecules that have reached various stages of clinical development, including two that have received marketing approval. He received a B.S. in chemistry from the University of California, Berkeley, and a Ph.D. in organic chemistry from Yale University.